Interventional Radiology Products Market Size, Share, Growth, and Industry Analysis, By Type (Ablation Probes, Biopsy Needles, Drainage Needles and Catheters, Needle Electrodes, Stents, Inferior Vena Cava (IVC) Filters, Embolization Devices, Others), By Application (Cardiology, Urology & Nephrology, Oncology, Gastroenterology, Neurology, Orthopedics, Others), Regional Insights and Forecast to 2035

Interventional Radiology Products Market Overview

The global Interventional Radiology Products Market is projected to expand steadily from USD 14137.24 Million in 2026 to USD 26946.86 Million by 2035, representing a CAGR of 7.43% during 2026-2035.

The Interventional Radiology Products Market is expanding as hospitals increasingly use minimally invasive, image-guided procedures to diagnose and treat cardiovascular disease, cancer, vascular disorders, neurological conditions, urological complications, and gastrointestinal abnormalities. Approximately 64% of current clinical adoption initiatives emphasize shorter procedural recovery, reduced surgical trauma, precise anatomical targeting, and lower dependence on open surgery. Stents represent the largest supplied product category because vascular and nonvascular interventions frequently require devices that restore or maintain vessel and duct patency. Embolization Devices are also gaining importance in oncology, neurological procedures, and bleeding control, while Ablation Probes increasingly support image-guided treatment of localized tumors. Biopsy Needles and Drainage Needles and Catheters remain essential across diagnostic and therapeutic workflows. Improvements in fluoroscopy, ultrasound, CT guidance, robotic navigation, cone-beam imaging, and three-dimensional planning are further expanding procedural accuracy and enabling treatment of increasingly complex patients through smaller access points.

The United States represents a major Interventional Radiology Products Market demand center because of extensive hospital infrastructure, advanced imaging capabilities, large cardiovascular and oncology patient populations, and broad clinical acceptance of minimally invasive intervention. Approximately 38% of global interventional radiology product demand is associated with North America, with the United States accounting for the majority of regional procedures. Hospitals continue to expand hybrid operating rooms, advanced angiography suites, and multidisciplinary interventional oncology programs capable of supporting complex embolization, ablation, stenting, drainage, biopsy, and vascular procedures. Cardiology remains a significant application because image-guided vascular treatment can reduce recovery requirements compared with open procedures. Oncology is also becoming increasingly important as Ablation Probes, Biopsy Needles, and Embolization Devices enable localized diagnosis and treatment while preserving surrounding tissue. Outpatient migration is further encouraging development of lower-profile devices, simplified delivery systems, and procedural technologies designed for faster recovery.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Market Driver: Growing preference for minimally invasive image-guided treatment is strengthening product adoption, with approximately 64% of expansion associated with cardiovascular, oncology, neurological, and vascular procedures requiring precise catheter-based intervention.
• Major Market Restraint: Limited specialist availability, complex procedural training, device costs, and uneven imaging infrastructure remain barriers, with approximately 36% of developing healthcare systems reporting constraints in advanced interventional radiology capability.
• Emerging Trends: Robotic navigation, AI-supported imaging, three-dimensional guidance, and advanced embolization are reshaping procedures, with approximately 52% of next-generation development activity emphasizing greater targeting accuracy, visualization, and workflow automation.
• Regional Leadership: North America leads the Interventional Radiology Products Market with approximately 38% share, supported by advanced imaging suites, strong specialist availability, high procedure volumes, and widespread adoption of minimally invasive treatment.
• Competitive Landscape: Manufacturers are expanding advanced stents, catheters, embolization platforms, and image-guided treatment portfolios, with approximately 41% of strategic initiatives focused on procedural simplification, lower-profile delivery, and more precise intervention.
• Market Segmentation: Stents lead supplied product types with 31% share, while Cardiology dominates supplied applications with 35% demand through vascular intervention, vessel support, minimally invasive treatment, and image-guided cardiovascular procedures.
• Recent Development: Device developers are accelerating robotics-compatible and image-integrated platforms, with approximately 28% of recent product innovation emphasizing real-time navigation, enhanced visualization, procedural precision, and minimally invasive delivery.

Latest Trends

Image-guided intervention is increasingly moving toward greater procedural automation, enhanced visualization, and more precise device navigation. Approximately 52% of advanced interventional radiology development activity now emphasizes robotic assistance, AI-supported imaging, real-time procedural guidance, or three-dimensional anatomical visualization. These technologies can help clinicians identify target anatomy, plan access routes, position devices, and monitor treatment response with greater consistency. Stents, embolization systems, Ablation Probes, and biopsy technologies increasingly benefit from improved imaging because precise placement directly influences procedural effectiveness. Hybrid operating rooms are also becoming more important as hospitals combine advanced imaging with surgical capability in the same environment, allowing teams to transition between minimally invasive and open techniques when necessary. Neurology and Cardiology applications particularly benefit from faster navigation and high-resolution visualization because interventions frequently involve small or difficult-to-access vessels.

Interventional oncology is another important trend as hospitals expand minimally invasive tumor diagnosis and treatment through biopsy, embolization, and thermal ablation. Approximately 31% of advanced image-guided oncology programs emphasize localized treatment that reduces injury to surrounding healthy tissue while shortening recovery. Ablation Probes are increasingly designed for controlled thermal delivery, while Embolization Devices are being refined for targeted vascular occlusion and tumor-directed procedures. Biopsy Needles are also becoming more precise as imaging guidance improves lesion targeting. Outpatient and shorter-stay procedures are encouraging manufacturers to reduce device profiles, simplify deployment, and improve procedural efficiency. These trends are broadening interventional radiology beyond traditional vascular intervention and strengthening its role across multidisciplinary cancer, neurological, gastrointestinal, and urological care.

Market Dynamics

Driver

"Minimally invasive image-guided treatment is expanding across multiple clinical specialties."

The strongest driver for the Interventional Radiology Products Market is the increasing clinical preference for procedures that can diagnose or treat disease through small access points rather than major open surgery. Approximately 64% of market expansion is associated with cardiovascular disease, cancer, vascular disorders, and other conditions where image-guided intervention can reduce procedural trauma. Interventional radiology products enable physicians to navigate through vessels or tissues while using fluoroscopy, ultrasound, CT, or related imaging to guide placement. Stents can restore vessel patency, Embolization Devices can selectively block blood flow, and Ablation Probes can destroy targeted tissue. Biopsy Needles and Drainage Needles and Catheters support diagnostic and therapeutic procedures that can often be completed without large surgical incisions.

Aging populations and rising chronic disease prevalence provide additional support because older patients frequently benefit from lower-trauma treatment approaches. Approximately 59% of high-volume interventional programs focus on Cardiology, Oncology, Urology & Nephrology, and neurological procedures involving minimally invasive access. Patients with multiple health conditions may have higher risk from major surgery, making catheter-based and percutaneous options particularly valuable. Hospitals are therefore expanding multidisciplinary interventional programs that combine radiologists, cardiologists, oncologists, neurologists, surgeons, and other specialists. This broader clinical integration increases demand for increasingly specialized needles, catheters, stents, filters, probes, electrodes, and embolization products.

Restraint

"Specialist shortages and advanced infrastructure requirements constrain wider adoption."

Interventional radiology requires specialist physicians, trained support teams, advanced imaging systems, sterile procedural environments, and sophisticated inventory management. Approximately 36% of healthcare systems in developing markets face limitations associated with specialist availability or advanced interventional infrastructure. Hospitals may require angiography systems, high-quality ultrasound, CT capability, anesthesia support, radiation protection, and dedicated recovery pathways before introducing complex procedures. These requirements can make adoption slower outside major urban medical centers. Device manufacturers therefore depend not only on product performance but also on the ability of healthcare systems to develop the clinical and technical infrastructure needed to use advanced interventional products safely.

Procedural cost and reimbursement complexity create another restraint because image-guided intervention can require premium disposable devices and expensive capital imaging equipment. Approximately 29% of procurement concerns involve procedural economics, reimbursement, inventory utilization, device standardization, and training costs. Hospitals may need to maintain multiple stent sizes, catheters, filters, embolization products, and needles to address variable anatomy and procedural requirements. Products with limited utilization can increase inventory pressure. Manufacturers are responding with broader platform standardization, simplified delivery systems, and training support designed to improve utilization and reduce procedural complexity.

Opportunity

"Interventional oncology and neurovascular treatment create major expansion opportunities."

Oncology represents one of the strongest opportunities because minimally invasive procedures can support both tumor diagnosis and localized therapy. Approximately 49% of emerging interventional oncology opportunities involve image-guided biopsy, embolization, ablation, drainage, and tumor-directed treatment. Ablation Probes enable clinicians to destroy selected lesions using controlled thermal energy, while Embolization Devices can reduce blood supply to targeted tissue. Biopsy Needles allow tissue diagnosis with smaller access routes than open surgical biopsy. These technologies can complement surgery, systemic therapy, radiation treatment, or palliative care, expanding the role of interventional radiology within multidisciplinary oncology pathways.

Neurology provides another important opportunity as hospitals expand endovascular treatment for complex cerebrovascular disorders. Approximately 46% of advanced neurological intervention programs emphasize precise vascular access, controlled embolization, stent deployment, and image-guided navigation. Small vessel size and complex cerebral anatomy create strong demand for lower-profile products and highly controlled delivery systems. Manufacturers that improve device flexibility, trackability, visibility, and deployment precision can strengthen adoption in neurointerventional centers. Advanced imaging and robotic navigation may further improve treatment capabilities as hospitals pursue greater procedural consistency.

Challenge

"Device precision and procedural safety must remain reliable in complex anatomy."

Interventional radiology products must perform reliably in vessels and anatomical structures that vary substantially between patients. Approximately 39% of advanced product engineering focuses on deliverability, trackability, flexibility, visibility, deployment accuracy, and atraumatic navigation. Stents must reach the intended location and expand predictably, while Embolization Devices must occlude selected vessels without unintended migration. Biopsy Needles and Ablation Probes require accurate positioning to obtain diagnostic tissue or treat lesions while avoiding critical surrounding structures. These requirements create significant engineering challenges because device dimensions must remain small even as physicians demand greater control and functionality.

Radiation exposure, procedural complexity, and workflow coordination create additional challenges. Approximately 42% of hospital interventional improvement programs emphasize imaging optimization, procedure-time reduction, navigation accuracy, and team coordination. Complex procedures can involve multiple devices, imaging sequences, and clinical specialists, increasing the potential for delays or errors. Manufacturers are therefore developing devices with improved visibility and more intuitive deployment mechanisms while imaging providers improve dose management and three-dimensional guidance. Training remains essential because even advanced devices require experienced clinicians capable of responding to unexpected anatomical or procedural conditions.

Market Segmentation

By Types

Ablation Probes: Ablation Probes account for approximately 9% of the supplied Interventional Radiology Products Market type segmentation and are increasingly used in Oncology and selected organ-specific procedures where clinicians seek localized destruction of abnormal tissue through image-guided access. These products support minimally invasive treatment strategies that can reduce surgical trauma while improving precision around targeted lesions.

Approximately 44% of Ablation Probes development activity focuses on more consistent energy delivery, improved thermal control, smaller probe profiles, and better compatibility with CT or ultrasound guidance. Manufacturers are refining probe geometry and temperature monitoring to help clinicians create predictable treatment zones while protecting nearby structures. Demand is strongest where localized tumor treatment can complement surgery, systemic therapy, or other image-guided intervention.

Biopsy Needles: Biopsy Needles represent approximately 12% of the supplied type segmentation and remain essential for obtaining tissue samples from suspicious lesions in Oncology, Gastroenterology, Urology & Nephrology, and other diagnostic pathways. Image guidance helps clinicians position needles accurately while minimizing unnecessary tissue disruption and reducing the need for open surgical biopsy in many cases.

Approximately 48% of Biopsy Needles development programs emphasize sharper targeting, improved echogenicity, lower tissue trauma, and compatibility with advanced imaging. Manufacturers are also improving sample quality and handling characteristics to support increasingly precise pathological and molecular assessment. Demand is strengthened by broader cancer screening and the growing use of image-guided diagnosis before treatment selection.

Drainage Needles and Catheters: Drainage Needles and Catheters account for approximately 11% of supplied product demand and are widely used for abscess drainage, fluid collection management, urinary drainage, biliary intervention, and other percutaneous procedures. These products are important across Gastroenterology, Urology & Nephrology, Oncology, and Acute Care because they allow controlled drainage without major surgery.

Approximately 46% of Drainage Needles and Catheters development focuses on kink resistance, secure placement, patient comfort, radiopacity, and reduced migration. Manufacturers are refining locking mechanisms and catheter materials to improve dwell stability in patients requiring extended drainage. Simplified kits are also helping standardize procedural setup and reduce preparation time in interventional suites.

Needle Electrodes: Needle Electrodes represent approximately 7% of the supplied Interventional Radiology Products Market type segmentation and support image-guided procedures involving electrical or thermal energy delivery. These products are relevant in selected Oncology and pain-related interventions where precise placement is necessary to reach target tissue while avoiding surrounding anatomical structures.

Approximately 39% of Needle Electrodes development emphasizes energy consistency, tip precision, insulation control, and improved visibility under imaging. Device designers are working to improve procedural confidence while supporting smaller access routes. Integration with advanced generators and monitoring systems is also helping clinicians manage treatment parameters more precisely.

Stents: Stents account for approximately 31% of the supplied type segmentation and remain the largest category because they are used across Cardiology, Neurology, Gastroenterology, Urology & Nephrology, and other interventional procedures requiring vessel or duct support. Their role in maintaining patency makes them central to both vascular and nonvascular intervention.

Approximately 58% of Stents development activity focuses on lower-profile delivery, improved flexibility, radial strength, visibility, and compatibility with complex anatomy. Manufacturers are also refining materials and deployment systems to improve trackability and placement accuracy. Cardiology remains the strongest application driver, but specialized stent designs continue to expand across neurological and nonvascular indications.

Inferior Vena Cava (IVC) Filters: Inferior Vena Cava (IVC) Filters represent approximately 8% of supplied product demand and are used in selected patients requiring protection against thromboembolic complications when conventional management is unsuitable or insufficient. These devices are positioned through minimally invasive vascular access and require accurate placement under image guidance.

Approximately 37% of IVC Filters development focuses on retrievability, deployment control, reduced migration, and improved long-term safety. Manufacturers are working to simplify retrieval and improve procedural visibility. Clinical use remains selective, which increases the importance of clear placement and follow-up protocols across vascular interventional programs.

Embolization Devices: Embolization Devices account for approximately 15% of the supplied type segmentation and are increasingly important across Oncology, Neurology, bleeding management, and selected vascular procedures. These products are used to deliberately block blood flow within targeted vessels, enabling treatment of tumors, vascular abnormalities, or hemorrhage through minimally invasive approaches.

Approximately 52% of Embolization Devices development emphasizes controlled deployment, predictable occlusion, smaller delivery systems, and improved visibility. Manufacturers are advancing coils, particles, plugs, and related delivery technologies to support more selective treatment. Interventional oncology and neurovascular procedures remain important growth areas because precise embolization can help clinicians treat difficult lesions while limiting exposure to surrounding tissue.

Others: Others represent approximately 7% of supplied product demand and include specialized interventional accessories and niche procedural devices used across multidisciplinary image-guided workflows. These products support access, positioning, delivery, monitoring, or procedural completion where standard device categories do not fully address specific clinical requirements.

Approximately 34% of innovation within the Others category focuses on procedural simplification, compatibility with imaging systems, lower-profile design, and improved usability. Suppliers serving this category often compete through specialized engineering and targeted clinical applications. Demand is influenced by continued expansion of minimally invasive procedures into increasingly complex anatomical and therapeutic areas.

By Applications

Cardiology: Cardiology accounts for approximately 35% of Interventional Radiology Products Market demand and represents the largest supplied application segment. Stents, catheters, filters, needles, and related devices are used across minimally invasive cardiovascular procedures where precise navigation, vessel support, and rapid restoration of blood flow are important.

Approximately 61% of Cardiology-focused development emphasizes lower-profile delivery, improved vessel access, enhanced imaging visibility, and compatibility with complex vascular anatomy. Hospitals increasingly favor minimally invasive cardiovascular treatment because it can reduce recovery time and procedural trauma. Demand remains especially strong in high-volume centers with advanced imaging and catheterization infrastructure.

Urology & Nephrology: Urology & Nephrology represent approximately 12% of supplied application demand and include drainage, stenting, biopsy, and image-guided interventions involving the kidneys, urinary tract, and related structures. Minimally invasive access can help clinicians manage obstruction, fluid accumulation, lesions, and selected complications without open surgery.

Approximately 43% of Urology & Nephrology product development focuses on catheter flexibility, drainage reliability, low-profile delivery, and patient comfort. Imaging-guided access supports precise placement in anatomically sensitive areas, while simplified drainage and stent systems can improve procedural efficiency. Demand is also supported by the growing burden of chronic kidney and urinary conditions.

Oncology: Oncology accounts for approximately 21% of supplied application demand and is one of the fastest-developing areas for interventional radiology products. Ablation Probes, Biopsy Needles, Embolization Devices, Drainage Needles and Catheters, and Needle Electrodes support both diagnosis and localized treatment of tumors.

Approximately 49% of Oncology-focused development emphasizes image-guided tissue targeting, localized ablation, tumor embolization, and minimally invasive biopsy. Hospitals increasingly integrate interventional radiology into multidisciplinary cancer care, allowing clinicians to combine imaging with targeted procedures that may reduce recovery burden. Advanced navigation and image fusion are improving treatment precision across difficult lesions.

Gastroenterology: Gastroenterology represents approximately 10% of supplied application demand and includes drainage, stenting, biopsy, and other image-guided procedures involving the gastrointestinal and hepatobiliary systems. Interventional radiology can help manage obstruction, fluid collections, lesions, and complications through percutaneous access.

Approximately 41% of Gastroenterology-related product development focuses on catheter flexibility, stent delivery, drainage efficiency, and compatibility with image-guided access. These devices help clinicians manage complex conditions while avoiding more invasive surgery in selected patients. Continued integration between gastroenterology and interventional radiology is broadening procedural options.

Neurology: Neurology accounts for approximately 11% of supplied application demand and includes image-guided vascular interventions involving the brain and surrounding circulation. Stents, Embolization Devices, catheters, and related delivery systems are used in selected neurovascular procedures where precision and trackability are critical.

Approximately 46% of Neurology-focused development emphasizes smaller device profiles, flexibility, radiographic visibility, and precise deployment. Neurovascular anatomy is highly complex, requiring devices capable of navigating tortuous vessels while maintaining control. Advanced imaging and navigation technologies are therefore especially important in this segment.

Orthopedics: Orthopedics represent approximately 6% of supplied application demand and include selected image-guided pain, biopsy, ablation, and minimally invasive skeletal procedures. Interventional products support treatment planning and targeted access in cases where conventional surgery may be more invasive than necessary.

Approximately 35% of Orthopedics-focused development emphasizes needle precision, imaging visibility, tissue targeting, and reduced procedural trauma. Demand remains more specialized than in Cardiology or Oncology, but image-guided intervention is expanding as clinicians adopt minimally invasive approaches for selected musculoskeletal conditions.

Others: Others account for approximately 5% of supplied application demand and include specialized image-guided procedures across multidisciplinary hospital departments. These applications use interventional products where precise access, drainage, embolization, biopsy, or support is required outside the principal listed specialties.

Approximately 33% of growth within the Others category is linked to expanding use of minimally invasive procedures in specialized clinical pathways. Manufacturers increasingly design versatile delivery systems and procedural accessories that can support a broader range of image-guided treatments without requiring entirely separate device platforms.

Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America leads the Interventional Radiology Products Market with approximately 38% share, supported by advanced hospital infrastructure, high procedural volumes, strong specialist availability, extensive cardiovascular and oncology treatment, and broad adoption of minimally invasive technologies. The United States remains the largest regional demand center because tertiary hospitals and academic centers continue to expand advanced interventional programs.

Approximately 62% of regional product adoption focuses on Cardiology, Oncology, Neurology, and complex vascular intervention. Hospitals are increasing use of hybrid operating rooms, robotic navigation, image fusion, and advanced embolization techniques. High reimbursement capacity and strong device availability also support rapid adoption of newer product platforms.

Europe

Europe represents approximately 27% of global Interventional Radiology Products Market demand, supported by mature healthcare systems, aging populations, advanced cardiovascular care, cancer treatment, and increasing use of image-guided procedures. Germany, the United Kingdom, France, Italy, Spain, and Nordic countries represent important demand centers.

Approximately 54% of European interventional expansion emphasizes minimally invasive oncology, vascular treatment, neurointervention, and improved procedural efficiency. Hospitals increasingly focus on reducing length of stay and treatment burden, supporting adoption of image-guided products. Clinical standardization and multidisciplinary care models also strengthen demand.

Asia-Pacific

Asia-Pacific accounts for approximately 25% of the Interventional Radiology Products Market and is expanding through hospital modernization, increasing cardiovascular and cancer treatment capacity, rising specialist availability, and improved imaging infrastructure. China, Japan, South Korea, India, and Australia represent major regional growth centers.

Approximately 63% of regional growth activity is associated with expansion of catheterization laboratories, oncology centers, advanced imaging suites, and specialist physician training. Local manufacturing and distribution are improving device availability, while premium hospitals increasingly adopt advanced Stents, Embolization Devices, and Ablation Probes.

Middle East and Africa

Middle East and Africa account for approximately 5% of global Interventional Radiology Products Market demand, supported by specialist hospitals, cardiovascular care, oncology investment, and medical infrastructure expansion. Gulf countries represent stronger adoption centers because of higher healthcare expenditure and advanced private hospital capacity.

Approximately 37% of regional opportunity is associated with Cardiology, Oncology, and image-guided vascular treatment. Adoption remains uneven across Africa because advanced interventional radiology requires specialist training and imaging infrastructure. Expansion of tertiary hospitals and medical tourism is expected to strengthen long-term demand.

Rest of the World

Rest of the World represents approximately 5% of the Interventional Radiology Products Market and includes Latin America and smaller developing healthcare regions. Brazil, Mexico, Argentina, and neighboring countries contribute through cardiovascular care, oncology treatment, and expanding minimally invasive procedure capacity.

Approximately 34% of future opportunity is linked to hospital modernization, improved access to advanced imaging, and greater specialist training. Cost sensitivity remains important, but leading urban hospitals increasingly adopt more sophisticated interventional platforms as procedural volumes rise.

List of Top Interventional Radiology Products Market Companies

• Medtronic
• Boston Scientific Corporation
• Becton, Dickinson and Company
• Abbott
• Cardinal Health
• B. Braun Melsungen AG
• Stryker
• Terumo Medical Corporation
• Cook Medical
• Biosensors International Group, Ltd
• Teleflex Incorporated
• iVascular S.L.U
• Penumbra, Inc
• BIOTRONIK SE & Co. KG
• ENDOCOR GmbH
• Meril Life Sciences Pvt. Ltd
• Palex Medical
• UreSil, LLC
• Alvimedica
• Cardionovum GmbH
• SMT
• Medinol Ltd
• Comed B.V.
• SCITECH
• Balton Sp. z o.o.
• Rontis

Top 2 Companies with Highest Market Share

• Medtronic: Medtronic is estimated to account for approximately 15% of relevant Interventional Radiology Products Market activity, supported by broad vascular and minimally invasive portfolios, global clinical relationships, and extensive participation across Cardiology and image-guided intervention.
• Boston Scientific Corporation: Boston Scientific Corporation is estimated to represent approximately 13% of relevant market activity, supported by advanced stents, embolization technologies, delivery systems, and strong participation across cardiovascular, oncology, and other interventional procedures.

Investment Analysis and Opportunities

Investment across the Interventional Radiology Products Market is increasingly directed toward robotic navigation, advanced embolization, image-guided oncology, lower-profile delivery systems, and digital procedural planning. Approximately 41% of strategic investment activity focuses on procedural simplification, precision targeting, and next-generation minimally invasive platforms. Manufacturers are also investing in physician training and clinical support because successful adoption depends heavily on procedural expertise and imaging capability.

Oncology and Neurology provide particularly attractive opportunities, with approximately 49% of emerging image-guided oncology activity associated with biopsy, embolization, ablation, and localized tumor treatment. Neurovascular intervention also supports investment in highly specialized products requiring improved flexibility and navigation. Suppliers capable of combining device innovation with imaging compatibility can capture higher-value procedural demand.

New Product Development

New product development is increasingly centered on lower-profile Stents, more controllable Embolization Devices, advanced Ablation Probes, and more visible Biopsy Needles. Approximately 43% of current engineering programs emphasize deliverability, deployment precision, imaging visibility, and compatibility with complex anatomy. Manufacturers are also improving delivery systems to reduce procedural steps and improve clinician control.

Digital integration is becoming increasingly important, with approximately 52% of next-generation development activity evaluating robotic navigation, AI-supported imaging, three-dimensional planning, or real-time procedural guidance. These technologies can help clinicians improve targeting and placement while reducing reliance on repeated imaging. Device manufacturers increasingly design products with these digital workflows in mind.

Five Recent Developments

• January 2026 – Advanced embolization platforms expand: Manufacturers increased development across at least 3 priorities involving delivery control, visibility, and selective vascular occlusion for complex interventions.
• March 2026 – Image-guided oncology systems strengthen: Device developers expanded localized treatment technologies, with approximately 49% of oncology innovation emphasizing biopsy, ablation, and embolization.
• April 2026 – Lower-profile stent systems advance: Suppliers strengthened at least 3 capabilities involving trackability, flexibility, and controlled deployment across difficult vascular anatomy.
• June 2026 – Robotic navigation integration broadens: Manufacturers increased development activity, with approximately 28% of recent innovation emphasizing image-integrated navigation and procedural precision.
• July 2026 – Biopsy and drainage kits improve: Suppliers expanded at least 3 areas involving simplified setup, better visibility, and improved procedural consistency across multidisciplinary interventional workflows.

Report Coverage

The Interventional Radiology Products Market report evaluates 8 supplied product types comprising Ablation Probes, Biopsy Needles, Drainage Needles and Catheters, Needle Electrodes, Stents, Inferior Vena Cava (IVC) Filters, Embolization Devices, and Others, together representing 100% of supplied type segmentation. Ablation Probes account for 9%, Biopsy Needles 12%, Drainage Needles and Catheters 11%, Needle Electrodes 7%, Stents 31%, Inferior Vena Cava (IVC) Filters 8%, Embolization Devices 15%, and Others 7%.

The report also covers 7 supplied applications representing 100% of demand, including Cardiology at 35%, Urology & Nephrology at 12%, Oncology at 21%, Gastroenterology at 10%, Neurology at 11%, Orthopedics at 6%, and Others at 5%. Regional shares represent 100% of the market, comprising North America at 38%, Europe at 27%, Asia-Pacific at 25%, Middle East and Africa at 5%, and Rest of the World at 5%. The assessment covers 26 supplied companies and evaluates minimally invasive treatment, image-guided intervention, device precision, embolization, stenting, biopsy, ablation, digital navigation, and procedural workflow development.

Interventional Radiology Products Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 14137.24 Million in 2026
Market Size Value By	USD 26946.86 Million by 2035
Growth Rate	CAGR of 7.43% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Ablation Probes Biopsy Needles Drainage Needles and Catheters Needle Electrodes Stents Inferior Vena Cava (IVC) Filters Embolization Devices Others By Application : Cardiology Urology & Nephrology Oncology Gastroenterology Neurology Orthopedics Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample